Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel in Refractory/Progressive Systemic Sclerosis
NCT06414135Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relmacabtagene autoleucel in systemic sclerosis (SSc). Primary endpoints: Dose Limiting Toxicity rate at 28 days and Adverse Events and Serious Adverse Events at 3 months. Started Jun 2024; status: recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06414135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414135.